Puoti M, et al. - The objective herein was to inspect the efficacy of glecaprevir plus pibrentasvir (G/P) in the treatment of hepatitis C virus (HCV) infection in subjects without cirrhosis. A 98% overall sustained virologic response 12 weeks post-treatment (SVR12) rate was obtained via G/P for 8 weeks in patients with chronic HCV GT1–6 infection without cirrhosis, regardless of baseline patient or viral characteristics. No notable rise was discovered in the SVR12 rate through 4 additional weeks of treatment. This, in turn, indicated that the optimal treatment duration in this population was 8 weeks.